Evidence from the BEACON CRC trial, a phase III study of a three-drug regimen that combined encorafenib with cetuximab plus binimetinib to treat an aggressive form of mCRC with BRAF V600E mutation improved survival without increasing the risk of serious side effects [28]. This evidence concerns the gene BRAF and colorectal carcinoma.